 Shares of pain management drug concern Collegium Pharmaceutical have fallen over 40 as the biotech selloff, negative attitudes towards opiates, and patent cliffs have taken a toll. The companys recent purchase of BioDelivery Sciences provides it with complementary suite of assets, an entry into neurology, and 75 million of cost synergies. 